Omidenepag isopropyl



Drug updated on 4/18/2024

Dosage FormSolution (topical ophthalmic; 0.02 mg/mL (0.002%))
Drug ClassRelatively selective prostaglandin E2 (EP2) receptor agonists
Ongoing and
Completed Studies


  • Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Omidenepag isopropyl (Omlonti) is indicated for the reduction of elevated intraocular pressure in individuals with open-angle glaucoma or ocular hypertension.
  • The information was derived from a study categorized as a Systematic Review / Meta-Analysis.
  • A meta-analysis assessed six studies involving 358 eyes from patients treated with omidenepag isopropyl for at least four weeks. These patients either had glaucoma or normal tension glaucoma.
  • There was a significant decrease in intraocular pressure with omidenepag isopropyl monotherapy among these patients. The weighted mean difference after treatment was -4.684, indicating a substantial reduction in elevated IOP levels.
  • Subgroups with initial IOP greater than 21 mmHg and those older than 65 years experienced significant reductions in IOP after using this medication, suggesting heightened effectiveness within these groups.
  • No differences were observed in the effectiveness of omidenepag isopropyl related to country of origin or dosage frequencies across various demographics and treatment regimens, indicating consistent results regardless of these variables.

Product Monograph / Prescribing Information

Document TitleYearSource
Omlonti (omidenepag isopropyl ophthalmic solution) Prescribing Information.2022Santen Incorporated, Emeryville, CA

Systematic Reviews / Meta-Analyses